Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taysha Gene TherapiesTSHA -2.71%33 Debt-to-Equity is 0.15 as of Jun. 2026, which is 72% below its 10-year median of 0.53. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 962 Biotechnology companies, Taysha Gene Therapies ranks better than 51.77% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Taysha Gene Therapies's Debt-to-Equity or its related term are showing as below:
TSHA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4 Med: 0.53 Max: 63.15
Current: 0.15
During the past 7 years, the highest Debt-to-Equity Ratio of Taysha Gene Therapies was 63.15. The lowest was -4.00. And the median was 0.53.
TSHA's Debt-to-Equity is ranked better than 51.77% of 962
companies
in the Biotechnology industry
Industry Median: 0.16
vs TSHA: 0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Taysha Gene Therapies Debt-to-Equity Related Terms
Taysha Gene Therapies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSHA vs KARD, GHRS, VIR: Debt-to-Equity Comparison
For the Biotechnology subindustry, Taysha Gene Therapies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a Debt-to-Equity of 0.15 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taysha Gene Therapies and its competitors. This is 72% below median its historical median of 0.53. According to the industry distribution chart, Taysha Gene Therapies ranks #464 out of 962 companies in the Biotechnology industry, placing it in the top 48.2%.
Is Taysha Gene Therapies' Debt-to-Equity too high?
Taysha Gene Therapies' current Debt-to-Equity of 0.15 is 72% below median its 10-year median of 0.53. The Biotechnology industry median Debt-to-Equity is 0.16. Taysha Gene Therapies' value of 0.15 is 6.3% below this industry median. Based on the distribution chart, Taysha Gene Therapies ranks #464 out of 962 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' Debt-to-Equity compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #464 out of 962 companies for Debt-to-Equity. This puts Taysha Gene Therapies in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Taysha Gene Therapies' value of 0.15 is 6.3% below this benchmark. While the company's 10-year median is 0.53 vs. the industry median of 0.16, Taysha Gene Therapies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taysha Gene Therapies's current Debt-to-Equity of 0.15 is 6.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Taysha Gene Therapies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current Debt-to-Equity is 0.15, which is 72% below median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current Debt-to-Equity is 0.15, which is 72% below median its 10-year median of 0.53 and 6.3% below the Biotechnology industry median of 0.16. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current Debt-to-Equity is 0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
Debt-to-Equity: 0.15 (72% below median its 10-year median of 0.53)
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
Industry Position: 6.3% below the Biotechnology median (#464 of 962)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
